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roentgenologic complex «ОperaT» (General Medical Merate GMM, Italy). Dorso-plantar and profile 
projection images were evaluated for diabetic osteoarthropathy early diagnostics. 
Results and discussions.   According to obtained data about foot tilt angle (α), in the first group 
81,7% patients had mild changes (I stage) , 12,1% - moderate (II stage), 3,1% - severe (III stage of 
flatfoot). In the second group I stage of flatfoot was diagnosed in 70,6% of patients, II stage – in 
23,6% and III stage – in 2,9%. In the 0 group only 23,3% patients had I stage of flatfoot and 76,7% - 
normal foot tilt angle. The calcaneus tilt angle (γ) was normal in 100% patients among 1, 2 and 0 
groups. The arch height (h) was normal only in 3,1% of the patients in 1 group, 2,9% - in 2 group and 
76,7% in 0 group. Only 3,1% patients in 1 group and 2,9%  in 2 group had normal anatomical and 
structural characteristics compared.  
Conclusions. According to the obtained data roentgenologic quantitative indexes, which 
include relation between height of the arch, foot length, width, foot tilt and calcaneus tilt angle, can 
be used as early criteria of screening diagnostics of Charcot osteoarthropathy in practice.  
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Introduction: Anticoagulation with vitamin K antagonist (VKA) has been an enduring gold 
standard for stroke prevention in AF as well as for the prophylaxis and long-term treatment of venous 
thromboembolism. But the potential for serious bleeding complications of the drug remains a problem 
for the safe use of drug. 
Aim: Examine the prevalence of thromboembolic and bleeding complications in patients with 
non-valvular atrial fibrillation who were receiving warfarin in Ukraine (Sumy) and who were 
receiving apixaban in Italy (Foggia). 
Metarials and methods. 35 Ukrainian patients were recruited between July 2015 and 
September 2016 and 25 Italian patients were observed during the period October 2016- February 
2017. They were divided into two groups: firsts group of patients who were taking warfarin and 
second group of patients who were taking apixaban.  We used the CHA2DS2VASc score to assess 
the risk of thromboembolic complications (TEC), scale HAS-BLED to assess the risk of bleeding, 
control of laboratory parameters (blood count, creatinine, glomerular filtration rate (GFR) by MDRD, 
coagulation).  
Results. The majority of patients (82%) were aged from 65 to 70 years. Apixaban 5 mg twice 
daily reduced stroke or systemic embolism by 21% compared with warfarin, combined with a 31% 
reduction in major bleeding and an 11% reduction in all-cause. Rates of haemorrhagic stroke and 
intracranial haemorrhage, but not of ischaemic stroke, were lower on apixaban.  
Conclusions. Both VKAs and NOACs are effective for the prevention of stroke in AF. 
Therefore, we recommend targeting the INR between 2.0 and 3.0 in patients on VKAs, maintaining 
a high TTR (e.g. ≥70% ), and to consider switching to a NOAC when a high TTR cannot be 
sustained. Apixaban dosing should follow the dose-reduction criteria evaluated in the clinical trials, 
considering renal function, age, and weight. Patient information and empowerment, best delivered 
through integrated AF management, seem paramount to achieve this goal. 
  
